Biotech Values

[biotech_researcher]

ARIAD- ASCO:
MMR rates were higher for ponatinib vs. imatinib at 3, 6, and 9 months (P=0.001):

At 3 months, ponatinib MMR was 31% of n=109 vs. imatinib MMR of 3% of n=114

At 6 months, ponatinib MMR was 62% of n=69 vs. imatinib MMR of 22% of n=73

At 9 months, ponatinib MMR was 86% of n=22 vs. imatinib MMR of 33% of n=27



If it wasn't for the toxicity, Ariad would redefine the space, imo.